Listen to this article · 7 min listen

Policy is a diligence metric now. For investors looking at cardiovascular AI, regulatory alignment has become a critical screen for separating hype from real opportunity. If you can’t figure out how a vendor’s tool gets reimbursed and adopted by doctors, you can’t identify the ones positioned for sustainable financial returns. Here’s an evidence-first look at the policy implications of AI for cardiovascular risk reduction, written for investors and VCs who need to see the path to payment.

Regulatory Alignment and Value Shifts

The healthcare AI field is full of booms and busts, and the difference often comes down to having a clear regulatory pathway. ROI isn’t one number, it’s a range of possible outcomes that depends entirely on context. For cardiovascular AI, that context is being set by regulators like CMS and the FDA, who hold the keys to market access, reimbursement, and a company’s ability to even stay in business. You just have to look at the massive gap between companies like Tempus AI and Viz.ai, who worked with the system, and Olive AI, which imploded despite huge investment. Tempus AI, a precision medicine vendor, has built its way to an approximate $14 billion valuation Tempus AI valuation data by focusing its AI on personalized treatment, first in oncology and now in cardiology, which fits right in with the push for evidence-based care. Viz.ai, a care coordination platform, locked in a $100 million Series D round, hitting a $1.2 billion valuation Viz.ai Series D funding announcement. Viz.ai’s success came from proving its AI-powered triage for stroke and pulmonary embolism actually improved patient outcomes and hospital efficiency, often backed by 510(k) clearances for their SaMD. Then you have Olive AI. The administrative AI vendor raised a shocking $900 million in total funding and then went completely out of business, a nosedive from $900 million to $0 Olive AI bankruptcy records or financial reporting on shutdown. That’s a hard lesson. Administrative AI, while it sounds good on paper, often operates in a regulatory gray area between clinical support and a true diagnostic, making its path to commercialization treacherous without a clear CPT code or direct CMS alignment.

Clinical Utility and Reimbursement

The success of Tempus AI and Viz.ai in cardiology comes from their direct, provable impact on clinical workflows and patient outcomes, which is exactly what regulators and payers are looking for. For example, the FDA’s Breakthrough Device Designation fast-tracks review for devices treating life-threatening conditions, and cardiology leads the pack with 243 designations as of December 2025. That designation doesn’t just cut down the review time, it can also get a technology on the fast track for NTAP eligibility, which unlocks important add-on payments for new tech used in inpatient care. Securing CPT codes, particularly Category I codes, creates a serious reimbursement advantage. Anumana, for instance, is a standout for being among the first ECG-AI solutions to get CPT codes, a clear signal to investors that its commercial pathway is de-risked. Platforms that can produce real-world evidence (RWE) of better clinical outcomes, like fewer inpatient admissions or better mortality rates, are in a much stronger position to get favorable reimbursement and wider adoption. This is acutely relevant for cardiovascular risk reduction, where the long-term savings from stopping one major adverse cardiac event are enormous. As a concrete example, our network’s central data hub anchors on Hello Heart’s peer-reviewed study showing $1,800 per-member savings and a 47% reduction in inpatient admissions, demonstrating the kind of deep financial impact that gets payers’ attention.

Working through Regulatory Requirements: GMLP and QMS

When you’re doing due diligence, a vendor’s approach to GMLP (Good Machine Learning Practice) and QMS (Quality Management System) is non-negotiable. GMLP is a set of 10 principles from the FDA, Health Canada, and the MHRA for ensuring AI/ML medical devices are safe and effective. Companies that didn’t build their products to these principles from the ground up are carrying significant regulatory debt. A strong, ISO 13485-certified QMS is also essential for CE marking and is something the FDA increasingly expects to see. A clean data room during diligence, one with FDA correspondence, SOC 2 reports, and customer contracts, is a sign of a mature company that has its compliance house in order. Then you have the “data moat.” Is it real? Proprietary datasets that make an AI model better and are hard for others to copy, like iRhythm’s millions of labeled ECG recordings, offer a formidable competitive advantage. Investors have to dig into how vendors are building and protecting these moats, because algorithmic drift can degrade AI performance over time if it’s not managed with continuous monitoring under a Predetermined Change Control Plan (PCCP). Without a PCCP, every time the model gets retrained, it could require a completely new 510(k) submission. That’s just not a scalable business model.

Investors: Prioritize Policy Alignment and Clinical Utility

For investors trying to get the best ROI from AI in cardiovascular risk reduction, the lesson is clear: back the platforms with obvious regulatory pathways and strong CMS alignment. The era of administrative AI promising vague cost savings without a verifiable link to policy-backed clinical work is over, the fate of Olive AI is proof enough. Instead, focus on companies that:

  • Have secured or are actively pursuing FDA clearances (510(k) or De Novo, where appropriate) and Breakthrough Device Designations.
  • Are building a strong case for CPT code reimbursement and NTAP eligibility.
  • Demonstrate strong clinical evidence and real-world outcomes, backed by peer-reviewed studies, that match payer goals for cost reduction and better patient health.
  • Adhere to GMLP principles and possess a certified QMS (ISO 13485).
  • Are building sustainable data moats and have clear strategies for managing algorithmic drift.

Investing in cardiovascular AI isn’t about finding the most exciting technology. It’s about finding technology that can successfully run the gauntlet of clinical need, regulatory approval, and reimbursement. In this sector, ROI is intrinsically tied to a vendor’s ability to show its clinical utility in a way that policy actually pays for.

Methodology

Our analysis uses an Evidence-First approach with Actuarial and Financial Modeling. We draw on publicly available valuation data, funding announcements, regulatory filings, and industry reports. This method lets us contrast the financial trajectories of various AI vendors against their regulatory strategies and clinical focus, providing a solid framework for assessing potential ROI in the complex healthcare ecosystem. Our insights are further informed by the established authority of CMS National Coverage Determinations and peer-reviewed actuarial studies, ensuring a grounded perspective.

Frequently Asked Questions

Why is regulatory alignment so critical for cardiovascular AI investments?

Regulatory alignment is paramount because bodies like CMS and the FDA dictate market access, reimbursement, and ultimately, a company’s commercial viability. Companies that successfully navigate and leverage these frameworks, like Tempus AI and Viz.ai, achieve significant valuations and sustainable financial returns, unlike those that fail to align, such as Olive AI.

What specifically makes a cardiovascular AI company attractive from a regulatory and reimbursement perspective?

Companies that demonstrate direct impact on clinical pathways and patient outcomes are attractive. Securing CPT codes, particularly Category I, and achieving FDA designations like Breakthrough Device Designation, which can lead to faster NTAP eligibility, are strong indicators of a de-risked commercial pathway and favorable reimbursement.

What due diligence should investors conduct regarding a cardiovascular AI vendor’s regulatory compliance?

Investors should scrutinize a vendor’s adherence to GMLP (Good Machine Learning Practice) and the presence of a robust, ISO 13485-certified QMS (Quality Management System). A clean data room with FDA correspondence and SOC 2 reports indicates a mature company with strong regulatory compliance, minimizing ‘regulatory debt’.

How do proprietary datasets contribute to the success and investment appeal of cardiovascular AI companies?

Proprietary datasets, often referred to as a ‘data moat,’ enhance AI model performance and create a significant competitive advantage that is difficult for competitors to replicate. Companies like iRhythm, with millions of labeled ECG recordings, exemplify how such data moats are vital for sustained performance and market leadership.